Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Liabilities and Shareholders Equity (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $130.9 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 37.52% to $130.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $640.5 million through Dec 2025, up 25.31% year-over-year, with the annual reading at $130.9 million for FY2025, 37.52% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $130.9 million at Artiva Biotherapeutics, down from $148.9 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $225.6 million in Q3 2024, with the low at $75.9 million in Q2 2024.
  • Average Liabilities and Shareholders Equity over 3 years is $157.1 million, with a median of $159.1 million recorded in 2025.
  • Peak annual rise in Liabilities and Shareholders Equity hit 123.14% in 2025, while the deepest fall reached 37.52% in 2025.
  • Over 3 years, Liabilities and Shareholders Equity stood at $105.1 million in 2023, then surged by 99.38% to $209.6 million in 2024, then tumbled by 37.52% to $130.9 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $130.9 million, $148.9 million, and $169.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.